Home » Topics » BioWorld Science

BioWorld Science
RSS

Algernon plans phase I study of AP-188 for stroke

June 18, 2021

FDA accepts IND for phase I trial of Xilio's XTX-101 in solid tumors

June 18, 2021

BriaCell advances personalized immunotherapies for prostate cancer, melanoma and lung cancer

June 18, 2021

Phase II results presented for ZYN-002 in children and adolescents with DEE

June 18, 2021

PureTech advances its wholly owned pipeline

June 18, 2021

Biogen discontinues gosuranemab based on phase II data in Alzheimer's disease

June 17, 2021

Loss of RKIP tied to aggressiveness in HNSCC

June 17, 2021

Early phase I data presented for LVGN-6051 as monotherapy and in combination with pembrolizumab

June 17, 2021

Therapeutic Solutions reports preclinical data on low-dose naltrexone for schizophrenia

June 17, 2021

China's NMPA approves initiation of clinical trials of anti-Claudin 18.2 ADC SYSA-1801

June 17, 2021

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...